Challenges in the US | Plenty to like
The US market is a key area of focus for a company covered here supporting the healthcare sector. As we anticipated, it’s proving a tough market to crack, but hopefully success will come. In the meantime expansion in other overseas markets is looking good and there is also a nice dividend to reward the patient. Read on here for our thoughts on the latest interim results as well as our usual forthright opinions on plenty of other updates, including the usual excellence from one of our Stonking Small Caps.
Client portfolios managed by our associates, Fundamental Asset Management, may hold shares in companies covered here. Fundamental manages a dedicated AIM IHT Income portfolio
Tristel: still all about US roll-out
Tristel (AIM: TSTL), the manufacturer of infection prevention products, announced decent interim results, although sales growth was lower than previous years and the US expansion continues to remain challenging as we reflect here.
The Company's core business is the sale to…
Continue reading our content…
- Unlimited access to our market-beating portfolios
- In-depth coverage of many of the world’s great companies
- Unique insights from our top research team
- Company and markets insights
- Sponsored content
- Podcasts
Previous article
